EUVIMEDEUVIMED entdecken
Crossref

Reply to: Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer

Nabil F Saba iD, Nofisat Ismaila iD, Francis Worden, Beth M Beadle iD

Journal of Clinical Oncology · 20.11.2026 · 44 (33) · 3285-3286

DOI: 10.1200/jco-26-01611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2026. Verfasst von Nabil F Saba und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nabil F. Saba, MD, Emory University, Atlanta, GA, Nofisat Ismaila, MD, American Society of Clinical Oncology (ASCO), Alexandria, VA, Francis Worden, …. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Nabil F. Saba, MD, Emory University, Atlanta, GA, Nofisat Ismaila, MD, American Society of Clinical Oncology (ASCO), Alexandria, VA, Francis Worden, MD, University of Michigan Rogel Cancer Center, Ann Arbor, MI, Beth M.…

ORCID-Profile: Nabil F Saba, Nofisat Ismaila, Beth M Beadle

Zitieren

APA

Saba, N. F., Ismaila, N., Worden, F., & Beadle, B. M. (2026). Reply to: Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer. Journal of Clinical Oncology, 44(33), 3285-3286. https://doi.org/10.1200/jco-26-01611

Vancouver

Saba NF, Ismaila N, Worden F, Beadle BM. Reply to: Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer. Journal of Clinical Oncology. 2026;44(33):3285-3286. doi:10.1200/jco-26-01611

BibTeX
@article{Saba2026,
  author = {Saba, Nabil F and Ismaila, Nofisat and Worden, Francis and Beadle, Beth M},
  title = {Reply to: Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {33},
  pages = {3285--3286},
  doi = {10.1200/jco-26-01611}
}
Kostenlos starten →